MediniceWAR:ICE +3.26%24 Current Ratio is 12.27 as of Mar. 2026, which is 62% above its 10-year median of 7.58. GuruFocus rates WAR:ICE with a GF Score™ of 24/100 and a GF Value™ of zł0.99 (Significantly Overvalued). The stock has 1 warning sign investors should review. Among 854 Medical Devices & Instruments companies, Medinice ranks better than 95.67% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Medinice's current ratio for the quarter that ended in Mar. 2026 was 12.27.
Medinice has a current ratio of 12.27. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Medinice's Current Ratio or its related term are showing as below:
WAR:ICE'
s Current Ratio Range Over the Past 10 Years
Min: 0.59 Med: 7.58 Max: 36.43
Current: 12.27
During the past 10 years, Medinice's highest Current Ratio was 36.43. The lowest was 0.59. And the median was 7.58.
WAR:ICE's Current Ratio is ranked better than 95.67% of 854
companies
in the Medical Devices & Instruments industry
Industry Median: 2.485
vs WAR:ICE: 12.27
Medinice (WAR:ICE) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Medinice Current Ratio Related Terms
Medinice Current Ratio Historical Data
* Premium members only.
The historical data trend for Medinice's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAR:ICE vs ABT, SYK, MDT: Current Ratio Comparison
For the Medical Devices subindustry, Medinice's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medinice Current Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Medinice's Current Ratio distribution charts can be found below:
* The bar in red indicates where Medinice's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medinice (WAR:ICE) has a Current Ratio of 12.27 as of Mar. 2026. This is 62% above median its historical median of 7.58. Over the past decade, Medinice's Current Ratio has ranged from 0.59 to 36.43. According to the industry distribution chart, Medinice ranks #37 out of 854 companies in the Medical Devices & Instruments industry, placing it in the top 4.3%.
Is Medinice's Current Ratio too high?
Medinice's current Current Ratio of 12.27 is 62% above median its 10-year median of 7.58. Over the past 10 years, this metric has ranged from a low of 0.59 to a high of 36.43. The Medical Devices & Instruments industry median Current Ratio is 2.49. Medinice's value of 12.27 is 393.8% above this industry median. Based on the distribution chart, Medinice ranks #37 out of 854 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Medinice has a GF Score™ of 24/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medinice's Current Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Medinice ranks #37 out of 854 companies for Current Ratio. This places Medinice in the top 4% of its industry — outperforming the majority of peers. The industry median Current Ratio is 2.49. Medinice's value of 12.27 is 393.8% above this benchmark. Historically, Medinice's own Current Ratio has ranged from 0.59 to 36.43 over the past decade. While the company's 10-year median is 7.58 vs. the industry median of 2.49, Medinice has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Medical Devices & Instruments company?
The median Current Ratio among Medical Devices & Instruments companies is 2.49, based on 854 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medinice's current Current Ratio of 12.27 is 393.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median Current Ratio is 2.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medinice's current Current Ratio is 12.27, which is 62% above median its own 10-year median of 7.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medinice stock overvalued right now?
Based on GuruFocus' analysis, Medinice (WAR:ICE) is currently considered Significantly Overvalued. The stock's GF Value™ is zł0.99, compared to a current price of zł76.10 — trading 7586.9% above its estimated fair value. The current Current Ratio is 12.27, which is 62% above median its 10-year median of 7.58 and 393.8% above the Medical Devices & Instruments industry median of 2.49. Medinice's overall GF Score™ is 24/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Medinice (WAR:ICE), the current Current Ratio is 12.27 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medinice (WAR:ICE) Overvalued in 2026?
Based on GuruFocus' analysis, Medinice stock appears to be overvalued.
The current stock price of zł76.10 is trading 7586.9% above its estimated GF Value™ of zł0.99.
GuruFocus considers Medinice to be Significantly Overvalued.
Key valuation signals for WAR:ICE:
Current Ratio: 12.27 (62% above median its 10-year median of 7.58)
GF Value™: zł0.99 vs. price of zł76.10 (7586.9% above fair value)
Industry Position: 393.8% above the Medical Devices & Instruments median (#37 of 854)
No single metric tells the full story. See the WAR:ICE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medinice SA is a Polish company operating in the MedTech industry. The company is engaged in creating, developing and commercializing solutions in the field of medicine, in particular, cardiology and cardio surgery. Its portfolio includes close around 12 projects including CathAIO, an electrode with universal diagnostic, electrophysiological, haemodinamic and biohemic functions and can be used for RF ablation; cryoapplicator, for minimally invasive cardiosurgical cryoablation; Med-iConsole allows to reduce the need to use multiple computer devices during electrophysiological treatment; Minimax and Pacepress.
24GF Score
Get the complete analysis for WAR:ICE
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:ICE has been successfully added to your 
